Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1206 • ACR Convergence 2020
Associations of Vascular and Bone Status in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Anita Pusztai¹, Attila Hamar², Monika Czókolyová², Katalin Gulyás², Ágnes Horváth², Edit Végh², Zsófia Pethő², Szilvia Szamosi², Emese Balogh², Nóra Bodnár², Ágnes Szentpétery³, Harjit Bhattoa², György Kerekes², Balázs Juhász², Éva Szekanecz², Katalin Hodosi², Andrea Domján², Sándor Szántó², Hennie Raterman⁴, Willem Lems⁵, Zoltán Szekanecz² and Gabriella Szűcs², ¹University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary, ²University of Debrecen, Debrecen, Hungary, ³Uppsala University Hospital, Uppsala, Sweden, ⁴Northwest Clinics, Alkmaar, Netherlands, ⁵Amsterdam Rheumatology and Immunology Centre, Amsterdam, Netherlands
Background/Purpose: Cardiovascular (CV) disease and osteoporosis (OP) have become increasing challenges in the ageing population, even more in patients with inflammatory rheumatic diseases, such as…
Abstract Number: 1223 • ACR Convergence 2020
Characterizing Rheumatoid Arthritis Patients by Their Biologic DMARD Prescription History
Piyam Das¹, Sicong Huang², Kumar Dahal², Huahua Zheng³, Jonathan Coblyn², Michael Weinblatt², Tianxi Cai¹ and Katherine Liao², ¹Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard School of Public Health, Boston, MA
Background/Purpose: IIn rheumatoid arthritis (RA), a patient’s biologic disease modifying anti-rheumatic drug (bDMARD) history and the duration of time they remain on each drug may…
Abstract Number: 1241 • ACR Convergence 2020
Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Tofacitinib or Biological DMARDs in Real Life Conditions in Two Latin America Countries
Hugo Madariaga¹, Juan Reyes², Magda Gutierrez³, Dario Ponce de Leon⁴, Tatjana Lukic⁵ and Luisa Amador², ¹Centro Medico CEEN, Arequipa, Arequipa, Peru, ²Pfizer, Bogota, Cundinamarca, Colombia, ³Pfizer, Santiago, Region Metropolitana, Chile, ⁴PFIZER, LIMA, Peru, ⁵Pfizer Inc, New York, NY
Background/Purpose: The objective of this study was to describe the efficacy, safety and patient reported outcomes in Latin-American patients with Rheumatoid Arthritis (RA) treated with…
Abstract Number: 1465 • ACR Convergence 2020
The Impact of the Combined Vaccination Scheme Against Streptococcus Pneumoniae on the Incidence of Related Infections in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARD: Data from BIOBADASER 3.0
Sebastian Rodriguez-Garcia¹, Carlos Sanchez-Piedra², Raul Castellanos-Moreira³, Dolores Ruiz-Montesinos⁴, Victoria Hernandez⁵, Manuel Pombo-Suarez⁶, Fernando Sanchez-Alonso², Loreto Carmona⁷ and JJ Gómez-Reino⁸, ¹La Princesa University Hospital, Madrid, Spain, ²Biobadaser, Research Unit, Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Clinic of Barcelona, Barcelona, Spain, ⁴Hospital Virgen Macarena, Sevilla, Spain, ⁵Hospital Clínic Barcelona, Barcelona, Spain, ⁶Hospital Clínico de Santiago, Santiago de Compostela, Spain, ⁷Instituto de Salud Musculoesquelética, Madrid, Spain, ⁸IDIS-CHUS - Rheumatology Group, Santiago de Compostela, Spain
Background/Purpose: Respiratory infections are among the leading causes of hospitalization in rheumatoid arthritis (RA) and Streptococcus Pneumoniae (SP) is one of the most frequent pathogens…
Abstract Number: 1547 • ACR Convergence 2020
Role of Artificial Intelligence in Assessment of Peripheral Joint MRI in Inflammatory Arthritis: A Systematic Review and Meta-analysis
Arya Haj-Mirzaian¹, Olga Kubassova², Mikael Boesen³, Paul Bird⁴ and John Carrino⁵, ¹Johns Hopkins Hospital, Baltimore, MD, ²Image Analysis Group, London, United Kingdom, ³Department of Radiology Copenhagen University hospital Bispebjerg and Frederiksberg; The Parker Institute, Copenhagen, Denmark, ⁴Optimus Clinical Research, Kogarah, University of New South Wales, Sydney, New South Wales, Australia, ⁵Hospital for Special Surgery, Hackensack, NJ
Background/Purpose: To summarize the feasibility, reliability, and validity of computer-aided quantification of joint destruction and synovitis on MRI using artificial intelligence (AI) based methods in…
Abstract Number: 1609 • ACR Convergence 2020
The Accuracy of Administrative Health Data for Identifying Patients with Rheumatoid Arthritis: A Validation Study Using Medical Records in Western Australia
Khalid Almutairi¹, Johannes Nossent¹, David Preen¹, Helen Keen¹, Katrina Rogers² and Charles Inderjeeth¹, ¹The University of Western Australia, Perth, Western Australia, Australia, ²Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
Background/Purpose: The use of large administrative health datasets is increasingly important in Rheumatology for disease trends and outcome research. We established the West Australian Rheumatic…
Abstract Number: 1725 • ACR Convergence 2020
An Investigation of the Relationship Between Patient Reported Outcomes and Biomarkers in a Community Rheumatology Practice
Elston He¹, Pratyusha Yalamanchi², William Arnold³ and Erin Arnold⁴, ¹Synovium, Inc., Philadelphia, PA, ²Michigan Medicine, Ann Arbor, MI, ³Retired, Wilmette, IL, ⁴Private Practice, Orthopaedics and Rheumatology of the North Shore, Wilmette, IL
Background/Purpose: Disease presentation and progression in rheumatoid arthritis (RA) is highly heterogeneous and requires careful consideration of outcome measurements to be used for individual patients.…
Abstract Number: 1742 • ACR Convergence 2020
Patients’ and Rheumatologists’ Perceptions on Preventive Intervention in Rheumatoid Arthritis and Axial Spondyloarthritis
Laurette van Boheemen¹, Janne Bolt², Marieke ter Wee³, Henriëtte de Jong², Marleen van de Sande⁴ and Dirkjan van Schaardenburg⁵, ¹Amsterdam Rheumatology and immunology Center | Reade, Amste, Netherlands, ²Amsterdam Rheumatology and immunology Center | Amsterdam UMC, Amsterdam, Netherlands, ³Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, ⁴Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁵Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: Persons at risk of developing rheumatoid arthritis (RA) may benefit from lifestyle1 or pharmacological2 interventions aimed at primary prevention. Although less studied, the same…
Abstract Number: 1759 • ACR Convergence 2020
Rheumatoid Arthritis Affects the Ossicular Joints: A Human Otopathologic Study
Melissa Castillo-Bustamante¹, Marc Polanik¹, Dhrumi Gandhi¹, Elliott Kozin¹ and Aaron Remenschneider¹, ¹Massachusetts Eye and Ear Infirmary/Harvard University, Boston, MA
Background/Purpose: Inflammation of synovial joints in small and large extremities is commonly seen in Rheumatoid arthritis (RA). To date little is known about how this disease…
Abstract Number: 1963 • ACR Convergence 2020
Variation in Quality of Care Among Patient Sociodemographic Groups in RISE Practices
Zara Izadi¹, Gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, Atherton, CA, ³University of California, San Francisco, San Francisco, CA
Background/Purpose: Previous studies have shown that sociodemographic factors are associated with quality of care. Using the Rheumatology Informatics System for Effectiveness (RISE) registry, we assessed…
Abstract Number: 2002 • ACR Convergence 2020
Incidence and Risk Factors for Herpes Zoster in Rheumatoid Arthritis Patients Receiving Upadacitinib
Kevin Winthrop¹, Peter Nash², Kunihiro Yamaoka³, Eduardo Mysler⁴, Leonard Calabrese⁵, Nasser Khan⁶, Jeffrey Enejosa⁶, Yanna Song⁷, Jessica Suboticki⁶ and Jeffrey Curtis⁸, ¹Oregon Health & Science University, Portland, OR, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ⁴Organización Medica de Investigación, Buenos Aires, Argentina, ⁵Cleveland Clinic, Cleveland, OH, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., North Chicago,, IL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Upadacitinib (UPA) is an oral JAK inhibitor approved for the treatment of rheumatoid arthritis (RA). The background rate of herpes zoster (HZ) in patients…
Abstract Number: PP09 • ACR Convergence 2020
An Integrative Approach to Managing Rheumatoid Arthritis (RA): Healing the Body, Mind & Spirit
Elisabeth Abeson¹, ¹Westport, CT

Background/Purpose: Diagnosed with RA in 2012, rheumatologists prescribed methotrexate or a biologic. As I was profoundly impacted by my mom’s 30-year battle with RA, I…
Abstract Number: 0017 • ACR Convergence 2020
Impact of COVID19 on Missed/Cancelled Rheumatology Office Visits and Parenteral Immunosuppressive Medications
Daniel Watrous¹, Glenn Parris², Priya Reddy³, Jeffrey Alper⁴, Fenglong Xie⁵, Maria (Maio) Danila⁶, Michael George⁷, William Nowell⁸, Joel Kallich⁹ and Jeffrey R Curtis¹⁰, ¹Sierra Pacific Arthritis, Visalia, CA, ²PARRIS & ASSOCIATES, Lilburn, GA, ³Southwest Florida Rheumatology, Riverview, FL, ⁴Medallion Clinical Research Institute, LLC, Naples, FL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Alabama at Birmingham (UAB), Birmingham, AL, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Global Healthy Living Foundation, New York City, NY, ⁹Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, ¹⁰Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The global COVID19 pandemic has had a major impact on healthcare. The effect on rheumatology patients and providers is unclear, as is the role…
Abstract Number: 0072 • ACR Convergence 2020
Characterizing Heterogeneity of Synovial Macrophages in Rheumatoid Arthritis Patients
Shang-Yang Chen¹, Yidan Wang², Anna Montgomery², Salina Dominguez², Carla Cuda², Gaurav Gadhvi¹, Harris Perlman² and Deborah Winter³, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University Division of Rheumatology, Chicago, IL
Background/Purpose: Macrophages in the synovial lining of the joint are critical players in the pathogenesis of rheumatoid arthritis (RA). While they are potent producers of…
Abstract Number: 0142 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs: Results from the FINCH 2 Study
Zobair Younossi¹, Maria Stepanova², Lynn Gerber¹, Susan Lee³, I-Heng Lee⁴, Thijs Hendrikx⁵, Annelies Boonen⁶, Rieke Alten⁷, Bernard Combe⁸ and David Walker⁹, ¹Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, ²Center for Outcomes Research in Liver Disease, Washington, DC, ³Gilead Sciences, Inc., Foster City, CA, ⁴Gilead Sciences, Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶Maastricht University Medical Center, Maastricht, Netherlands, ⁷Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ⁸University of Montpellier, Montpellier, France, ⁹Northumbria Healthcare Trust, North Shields, United Kingdom
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor which is currently being investigated as an agent to treat rheumatoid arthritis (RA).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].